Remimazolam: What Is It?
Article Sidebar
Main Article Content
Abstract
Remimazolam (CNS 7056) is a new rapidly metabolized benzodiazepine and has been presented in clinical research protocols. It is water-soluble and when diluted into a solution becomes a painless injectate. Remimazolam is most soluble in slightly acidic environments and can precipitate in lactated or acetated Ringer’s solution.1 It has promising characteristics as a sedative drug in clinical anesthesia because of its rapid onset of action, ultra short duration, and fast recovery time. Midazolam is the parent compound of remimazolam; therefore, remimazolam has a gamma-aminobutyric acid (GABA) neurotransmitter receptor mechanism of action. Remimazolam is rapidly metabolized by non-specific esterases, mainly localized in the human liver. After administration, plasma concentrations of remimazolam certainly and rapidly decrease, and with adequate dosing, there is no prolonged sedative effect.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Yoshida K, Tanaka S, Watanabe K. A case of intravenous line occlusion when using acetated Ringer’s solution and remimazolam. J Clin Anesth. 2021;70:110190.
Morimoto Y. Efficacy and safety profile of remimazolam for sedation in adults undergoing short surgical procedures. Ther Clin Risk Manage. 2022;18:95-100.
Amornyotin S. Sedative and analgesic drugs for gastrointestinal endoscopic procedure. J Gastroenterol Hepatol Res. 2014;3:1133-44.
Amornyotin S. Anesthesia innovations for endoscopy of gastrointestinal tract. In: Somchai Amornyotin (Ed.). Endoscopy-innovative uses and emerging technologies, ISBN: 978-953-51-2172-5, Croatia, InTech. 2015:39-61.
Ul-Haque I, Shaikh T, Ahmed S, et al. Efficacy of remimazolam for procedural sedation in American Society of Anesthesiologists (ASA) I to IV patients undergoing colonoscopy: a systematic review and meta-analysis. Cureus. 2022;14:e22881.
Pastis NJ, Yarmus LB, Schippers F, Pritchett MA, Silvestri GA. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest. 2019;155:137-46.
Pedersena MH, Danø A, Englev E, Kattenhøjb L, Munk E. Economic benefits of remimazolam compared to midazolam and propofol for
procedural sedation in colonoscopies and
bronchoscopies. Curr Med Res Opion. 2023;39:
-9.
Sheng XY, Liang Y, Yang XY, et al. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol. 2020;76:383-91.
Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020;34:543-53.
Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial.
J Anesth. 2020;34:491-501.
Kempenaers S, Hansen TG, van de Velde M. Remimazolam and serious adverse events. A scoping review. Eur J Anaesthesiol. 2023;40:
-53.
Kimoto Y, Hirano T, Kuratani N, Cavanaugh D, Mason KP. Remimazolam as an adjunct to general anesthesia in children: adverse events and outcomes in a large cohort of 418 cases. J Clin Med. 2023;12:3930.
Chen J, Zou X, Hu B, et al. Remimazolam vs etomidate: haemodynamic effects in hypertensive elderly patients undergoing non-cardiac surgery. Drug Design Develop Ther. 2023;17:2943-53.
Zhao YR, Huang KS, Hou G, et al. Efficacy and safety of remimazolam-based sedation for intensive care unit patients undergoing upper gastrointestinal endoscopy: a cohort study. World J Emerg Med. 2023;14:31-6.
Xiao Y, Wei R, Chen L, Chen Y, Kong L. Efficacy and safety of remimazolam for procedural sedation during ultrasound-guided transversus abdominis plane block and rectus sheath block in patients undergoing abdominal tumor surgery: a single-center randomized controlled trial. BMC Anesthesiol. 2022;22:381.
Zhang J, Cairen Z, Shi L, et al. Remimazolam versus propofol for procedural sedation and anesthesia: a systemic review and meta-analysis. Minerva Anestesiol. 2022;88:1035-42.
Dou D, Feng Y, Jiang L. Efficiency and safety of
remimazolam and midazolam in digestive
endoscopic sedation: systematic review and meta-
analysis. Dig Endosc. 2022;34:653.
Ko CC, Hung KC, Illias AM, et al. The use of remimazolam versus propofol for induction and maintenance of general anesthesia: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1101728.
FDA. BYFAVO™ (remimazolam) FDA packet insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf Accessed August 8, 2023.
Abcejo AS, Teixeira MT. Remimazolam: patient safety considerations of a novel, practice-changing drug in perioperative medicine. APSF Newsletter. 2023;38:80-3.